Противовоспалительная терапия хронической обструктивной болезни легких: настоящее и будущее
Аннотация
Сегодня хроническая обструктивная болезнь легких представляет собой значительную экономическую и социальную проблему и является единственной болезнью, при которой смертность продолжает увеличиваться [4, 5]. По данным ряда недавно выполненных исследований, распространенность хронической обструктивной болезни легких в мире у людей старше 40 лет составляет 10,1% (11,8% у мужчин и 8,5% у женщин) [3].
Список литературы
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2011. wwwgoldcopd.org/.
2. Celli B.R., MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
3. Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-50.
4. Mannino D.M., Homa D.M., Akinbami L. et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill Summ 2002; 51: 1-16.
5. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
6. Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-88.
7. Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709-21.
8. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-80.
9. Barnes PJ. Molecular genetics of chronic obstructive pulmonary disease. Thorax 1999; 54: 245-52.
10. Meshi B., Vitalis T.Z., Ionescu D., Elliott W.M., Liu C., Wang X.D. et al. Emphysematous lung destruction by cigarette smoke. The effects of latent adenoviral infection on the lung inflammatory response. Am J Respir Cell Mol Biol 2002; 26: 52-7.
11. Ito K., Barnes PJ., Adcock I.M. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1b-induced histo-ne H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000; 20: 6891-903.
12. Hogg J.C., Macklem P.T., Thurlbeck W.M. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278: 1355-1360.
13. O'Donnell R.A., Peebles C., Ward J.A. et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophi-lic inflammation in COPD. Thorax 2004; 59: 837-842.
14. Nadel J.A. Role of neutrophil elastase in hypersecretion during COPD exacerbations, and proposed therapies. Chest 2000; 117: Suppl. 2, 386S-389S.
15. Finkelstein R., Ma H.D., Ghezzo H. et al. Morphometry of small airways in smokers and its relationship to emphysema type and hyperresponsiveness. Am J Respir Crit Care Med 1995; 152: 267-276.
16. Frankenberger M., Menzel M., Betz R. et al. Characterization of a population of small macrophages in induced sputum of patients with chronic obstructive pulmonary disease and healthy volunteers. Clin Exp Immunol 2004; 138: 507-516.
17. Saetta M., Mariani M., Panina-Bordignon P. et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165: 1404-1409.
18. Fairclough L., Urbanowicz R.A., Corne J., et al. Killer cells in chronic obstructive pulmonary disease. Clin Sci (Lond) 2008; 114: 533-541.
19. Grashoff W.F., Sont J.K., Sterk PJ., et al. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am J Pathol 1997; 151: 1785-1790.
20. Saetta M., Di Stefano A., Maestrelli P., et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150: 1646-1652.
21. Papi A., Bellettato C.M., Braccioni F., et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114-1121.
22. Snoeck-Stroband JB, Lapperre TS, Gosman MM, et al. Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. Eur Respir J 2008; 31: 70-77.
23. Rutgers SR, Postma DS, ten Hacken NH, Kauffman HF, Der Mark TW, ter GH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55: 12-18.
24. Antoniu S.A. New therapeutic options in the management of COPD - focus on roflumilast. Int J Chron Obstruct Pulmon Dis 2011; 6: 147-155.
25. Yamaya M, Azuma A, Takizawa H. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J 2012; 40: 485-494.
26. Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev 2009; 18: 1-11.
27. Cazzola M, Dahl R. Inhaled combination therapy with long-acting p2-agonists and corticosteroids in stable COPD. Chest 2004; 126: 220-237.
28. Hanania NA. The impact of inhaled corticosteroid and long-acting b-agonist combination therapy on outcomes in COPD. Pulmon Pharmacol Ther 2008; 21: 540-550.
29. Welte T. Optimising treatment for COPD – new strategies for combination therapy. Int J Clin Pract 2009; 63: 1136–1149
30. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002; 19: 182–191.
31. Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542–548.
32. Gan WQ, Man SF, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005; 5: 3.
33. Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007; 62: 938–943.
34. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, ten Hacken NH, Sont JK, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009; 151: 517–527.
35. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592–1596.
36. Barnes NC, Qiu Y-S, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736–743.
37. Jen R, Rennard SI, Sin DD. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J COPD 2012; 7: 587-595.
38. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967–1976.
39. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953.
40. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK on behalf of the ISOLDE study investigators. Randomised, double blind, placebo controled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Brit Med J 2000; 320: 1297-1303.
41. Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60: 480–487.
42. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789.
43. Cyr M-C, Beauchesne M-F, Lemière C, et al. Effects of inhaled corticosteroids in monotherapy or combined with long-acting β2-agonists on mortality among patients with chronic obstructive pulmonary disease. Ann Pharmacotherapy 2010; 44: 613-622.
44. Hubbard RF, Tattersfield AF, Smith CF, et al. Use of inhaled corticosteroids and the risk of fracture. Chest 2006; 130: 1687–1688.
45. Weatherall M, Clay J, James K, Perrin K, Shirtcliffe P, Beasley R. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology 2009; 14: 983–990.
46. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Amer J Med 2010; 123: 1001-1006.
47. Grootendorst DC, Gauw SA, Verhoosel RM, et al. The PDE4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Thorax 2007; 62: 1081–7.
48. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011; 163: 53–67.
49. Rabe KF, Bateman ED, O’Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2005; 366: 563–571.
50. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-694
51. Rennard SI, Calverley PMA, Goehring UM, Bredenbröker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respiratory Research 2011, 12: 18.
52. Bateman ED, Rabe KF, Calverley PMA, et al. Roflumilast with long-acting b2-agonists for COPD: influence of exacerbation history. Eur Respir J 2011; 38: 553–560
53. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154–161.
54. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695–703.
55. Tenor H HA, Beume R, Lahu G, Zech K, Bethke T. Pharmacology, clinical efficacy and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics. In: Francis SH et al. (eds). In “Phosphodiesterases as drug targets, handbook of experimental pharmacology 204”. Berlin Heidelberg: Springer-Verlag; 2011.
56. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004; 117(Suppl. 9A): 5S–11S.
57. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997; 156: 266–271.
58. Stamatiou R., Paraskeva E., Boukas K. et al. Azithromycin has an antiproliferative and autophagic effect on airway smooth muscle cells. Eur Respir J 2009; 34: 721-730.
59. Murphy DM, Forrest IA, Ward C, et al. Effect of azithromycin on primary bronchial epithelial cells derived from stable lung allografts. Thorax 2007; 62: 834.
60. Vanaudenaerde BM, Meyts I, Vos R, et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008; 32: 832-842.
61. Mitsuya Y, Kawai S, Kobayashi H. Influence of macrolides on guanosine diphospho-D-mannose dehydrogenase activity in Pseudomonas biofilm. J Infect Chemother 2000; 6: 45–50.
62. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-98.
63. Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Inf Dis 2005; 40: 1288–97.
64. Cymbala AA, Edmonds LC, Bauer MA, et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005; 4: 117–22.
65. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366: 1881-90.
66. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006; 61: 729-34.
67. Roche N., Marthan R., Berger P., et al. Beyond corticosteroids: future prospects in the management of inflammation in COPD. Eur Respir Rev 2011; 20: 121, 175–182.
68. Young RP, Hopkins R, Eaton TE. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J 2009; 85: 414–421.
69. Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009; 9: 32.
70. Janda S, Park K, Fitzgerald M, et al. Statins in COPD. A systematic review. Chest 2009; 136: 734–743.
71. Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence form a retrospective cohort study. Int J Clin Pract 2008; 62: 1373–1378.
72. Soyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality of COPD. Eur Respir J 2007; 29: 279–283.
73. Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10: 45.
74. Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007; 132: 1764-1771.
75. Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007; 176: 742–747.
76. Lee TM, Lin MS, Chang NC. Usefulnes of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008; 101: 530–535.
77. Barnes PJ. Emerging pharmacotherapies for COPD. Chest 2008; 134; 1278-1286.
78. De Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Сrit Care Med 1996; 153: 633–637.
79. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Сrit Care Med 2007; 175: 926–934.
80. Cazzola M, Page CP, Calzetta L, Matera MG. Emerging anti-inflammatory strategies for COPD. Eur Respir J 2012; 40: 724–741.
81. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing lnterleukin-8 in COPD: a pilot study. Chest 2004; 126: 926–934.
82. Gompertz S, Stockley RA. A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 2002; 122: 289–294.
83. Rafii R, Albertson TE, Louie S, Chan AL. Update on Pharmaceutical andMinimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease. Pulm Med 2011, doi:10.1155/2011/257496.
Просмотров: 150
.jpg)
Послать статью по эл. почте 